Immunity Research Co., Ltd. Notice of Strategic Capital and Business Alliance between Towns Co., Ltd. and Immunity Research Co., Ltd.

Immunity Research Co., Ltd.
Notice of Strategic Capital and Business Alliance between Towns Co., Ltd. and Immunity Research Co., Ltd.

Towns Co., Ltd. (Headquarters: Izunokuni City, Shizuoka Prefecture, President: Masaki Nonaka, hereinafter Towns) and Immunity Research Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, Representative Director: Masafumi Yasukochi, hereinafter Immunity Research) have established 3 We are pleased to announce that Townes has underwritten a third-party allotment of 100 million yen worth of shares, and that we have concluded a business alliance agreement for the development of in-vitro diagnostic drugs and diagnostic services that utilize immune cell analysis technology.
[Image 1

[Image 2

Townes is one of the major companies in the field of in-vitro diagnostics, and manufactures in-vitro diagnostics that apply various diagnostic technologies and sells them domestically and
internationally. In particular, the pandemic of the new coronavirus, which began in 2020, still has a significant impact on people’s lives and the global economy as a whole, and the importance of antigen test kits developed by Towns, including dealing with mutant strains, is increasing. I’m here.
On the other hand, Immunity Research owns the patent license that enables extremely effective and easy prediction of the effects of immune checkpoint inhibitors in cancer treatment using its unique immune cell analysis technology.
Effective immune cell analysis is essential for the in vitro diagnostic drugs developed by Towns, and through this partnership, Towns will use Immunity Research’s immune cell analysis technology in product development to create a more useful and high value-added companion. We will promote the development of in-vitro diagnostic agents, including the development of diagnostic agents.
Regarding this partnership, Mr. Nonaka, President and CEO of Towns, and Mr. Yasukochi, President and CEO of Immunity Research, have made the following comments.
Towns CEO Nonaka’s comment
The companion diagnosis of immune checkpoint inhibitors by Immunity Research is a very promising product that can be expected to reduce the burden on patients in addition to high accuracy. In addition, since the company’s technology is expected to be applied to a wide range of fields, we have positioned it as one of the most important fields in the future, and will cooperate with each other to develop more useful in-vitro diagnostics.
Comment from Yasukochi, Representative Director of Immunity Research We are very happy to have established a strategic capital and business alliance with Towns, a leader in the in-vitro diagnostics industry, who appreciated our technology. We have developed an immune cell analysis system to understand the immune status, and we are looking for diagnostic biomarkers and drug targets by analyzing immune cells. We started with development related to cancer immunity, but we will expand to fields such as neurological diseases and lifestyle-related diseases. In the future, through TOWNS’ products and network, we hope to aim to solve health problems in the world with our developed products.
[About Towns]
Townes is an R&D-oriented manufacturer founded in Numazu City, Shizuoka Prefecture in 1987 with strengths in diagnostic technology. Under the corporate slogan, “Diagnostic technology for a safer day,” we have launched antigen test kits that make use of our many years of know-how in the field of respiratory infections. In recent years, through capital and business alliances with multiple bio-ventures, we are working to solve problems in the areas of
prevention/pre-symptomatic disease and diagnosis of chronic diseases. 《https://www.tauns.co.jp/》
[About Immunity Research]
Immunity Research is a venture from Saitama Medical University, founded in 2017. Based on multiple patents that can predict the effects of immune checkpoint inhibitors, we develop and operate the immune profiling automation system “rippleT”. In August 2022, we also expanded into the Kobe Biomedical Innovation Cluster for further research and development of the “Immune Cell Analysis Service.” Please refer to the company website <

rehow

%d bloggers like this: